IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Biologics: Targets and Therapy

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on June 27, 2025

Impact Score

2024-2025

3.23

h-Index

2024-2025

 50

Rank

2024-2025

 2106

SJR

2024-2025

 1.612

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Biologics: Targets and Therapy
Abbreviation Biol.: Targets Ther.
Publication Type Journal
Subject Area, Categories, Scope Gastroenterology (Q1); Immunology and Allergy (Q1); Oncology (Q1); Pharmacology (medical) (Q1); Rheumatology (Q1)
h-index 50
Overall Rank/Ranking 2106
SCImago Journal Rank (SJR) 1.612
Impact Score 3.23
Publisher Dove Medical Press Ltd.
Country New Zealand
ISSN 11775491, 11775475
Best Quartile Q1
Coverage History 1988, 2007-2025




About Biologics: Targets and Therapy


Biologics: Targets and Therapy is a journal covering the technologies/fields/categories related to Gastroenterology (Q1); Immunology and Allergy (Q1); Oncology (Q1); Pharmacology (medical) (Q1); Rheumatology (Q1). It is published by Dove Medical Press Ltd.. The overall rank of Biologics: Targets and Therapy is 2106. According to SCImago Journal Rank (SJR), this journal is ranked 1.612. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 50. The best quartile for this journal is Q1.

The ISSN of Biologics: Targets and Therapy journal is 11775491, 11775475. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Biologics: Targets and Therapy is cited by a total of 491 articles during the last 3 years (Preceding 2024).


Biologics: Targets and Therapy Impact IF 2024-2025


The Impact IF 2024 of Biologics: Targets and Therapy is 3.23, which is computed in 2025 as per its definition. Biologics: Targets and Therapy IF is decreased by a factor of 2.58 and approximate percentage change is -44.41% when compared to preceding year 2023, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Biologics: Targets and Therapy Impact IF 2025 Prediction


Impact IF 2024 of Biologics: Targets and Therapy is 3.23. If the same downward trend persists, Impact IF may fall in 2025 as well.


Impact IF Trend


Year wise Impact IF of Biologics: Targets and Therapy. Based on Scopus data.


Year Impact IF
2025/2026 Coming Soon
2024 3.23
2023 5.81
2022 4.21
2021 5.14
2020 4.44
2019 2.81
2018 2.13
2017 2.82
2016 3.74
2015 4.90
2014 4.22

Biologics: Targets and Therapy h-index


  Table Setting

Biologics: Targets and Therapy has an h-index of 50. It means 50 articles of this journal have more than 50 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Biologics: Targets and Therapy ISSN


The ISSN of Biologics: Targets and Therapy is 11775491, 11775475. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Biologics: Targets and Therapy Rank and SCImago Journal Rank (SJR)


The overall rank of Biologics: Targets and Therapy is 2106. According to SCImago Journal Rank (SJR), this journal is ranked 1.612. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Biologics: Targets and Therapy by Year


Year SJR
2025/2026 Coming Soon
2024 1.612
2023 1.276
2022 1.176
2021 0.832
2020 0.948
2019 0.697
2018 0.683
2017 1.084
2016 1.133
2015 1.172
2014 1.096

Ranking of Biologics: Targets and Therapy by Year


Year Ranking
2025/2026 Coming Soon
2024 2106
2023 2958
2022 3191
2021 5414
2020 4733
2019 6993
2018 7038
2017 3907
2016 3649
2015 3529
2014 3794

Biologics: Targets and Therapy Publisher


Table Setting

Biologics: Targets and Therapy is published by Dove Medical Press Ltd.. It's publishing house is located in New Zealand. Coverage history of this journal is as following: 1988, 2007-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Biologics: Targets and Therapy is Biol.: Targets Ther.. This abbreviation ('Biol.: Targets Ther.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Biologics: Targets and Therapy


If your research field is/are related to Gastroenterology (Q1); Immunology and Allergy (Q1); Oncology (Q1); Pharmacology (medical) (Q1); Rheumatology (Q1), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Biologics: Targets and Therapy?

Biologics: Targets and Therapy latest impact IF is 3.23. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 5.81 (2023) and 2.13 (2018), respectively, in the last 11 years. Moreover, its average IS is 3.95 in the previous 11 years.


What's the SCImago Journal Rank (SJR) of the Biologics: Targets and Therapy?

The Biologics: Targets and Therapy has an SJR (SCImago Journal Rank) of 1.612, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 1.612 in 2024 and the lowest being 0.683 in 2018. Furthermore, the average SJR of the Biologics: Targets and Therapy over the previous 11-year period stands at 3.95.


What's the latest h-index of the Biologics: Targets and Therapy?

The latest h-index of the Biologics: Targets and Therapy is 50.


Who's the publisher of the Biologics: Targets and Therapy?

The Biologics: Targets and Therapy is published by the Dove Medical Press Ltd., with its country of publication being the New Zealand.


What's the current ranking of the Biologics: Targets and Therapy?

The Biologics: Targets and Therapy is currently ranked 2106 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 2106 in 2024 and its lowest position of 7038 in 2018.


What's the abbreviation or short name for the Biologics: Targets and Therapy?

The standard ISO4 abbreviation for the Biologics: Targets and Therapy is Biol.: Targets Ther..


Is the "Biologics: Targets and Therapy" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Biologics: Targets and Therapy is classified as a journal that the Dove Medical Press Ltd. publishes.


What's the scope or major areas of the Biologics: Targets and Therapy?

The Biologics: Targets and Therapy encompasses the following areas:

  • Gastroenterology
  • Immunology and Allergy
  • Oncology
  • Pharmacology (medical)
  • Rheumatology

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Biologics: Targets and Therapy?

The Biologics: Targets and Therapy is assigned the following International Standard Serial Numbers (ISSN): 11775491, 11775475.


What's the best quartile of the Biologics: Targets and Therapy?

The best quartile for the Biologics: Targets and Therapy is Q1 (2024).


What's the coverage history of the Biologics: Targets and Therapy?

The Biologics: Targets and Therapy coverage history can be summarized as follows: 1988, 2007-2025.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Journal of Business Economics and Management journal 9811 Vilnius Gediminas Technical University 55 2.84
Journal of Academic Ethics journal 8704 Springer Netherlands 34 4.04
European Union Politics journal 1953 SAGE Publications Ltd 79 3.71
Entrepreneurship Theory and Practice journal 168 SAGE Publications Ltd 212 13.35
Discourse journal 7536 Routledge 70 2.75
Marine Biology Research journal 14618 Taylor and Francis Ltd. 47 1.21
European Journal of Cancer, Supplement journal 13149 Elsevier Ltd 30 0.00
European Journal of Wildlife Research journal 10254 Springer Verlag 62 1.99
Clinical Interventions in Aging journal 4023 Dove Medical Press Ltd. 114 3.68
PLoS ONE journal 6756 Public Library of Science 467 2.82

Check complete list




Year wise Impact Score (IS) of Biologics: Targets and Therapy

Impact Score Table

Year Impact Score (IS)
2025/2026 Coming Soon
2024 3.23
2023 5.81
2022 4.21
2021 5.14
2020 4.44
2019 2.81
2018 2.13
2017 2.82
2016 3.74
2015 4.90
2014 4.22



Top Journals/Conferences in Gastroenterology

Lancet Gastroenterology and Hepatology, The
Elsevier Ltd | United Kingdom

Nature Reviews Gastroenterology and Hepatology
Nature Research | United Kingdom

Gut
BMJ Publishing Group | United Kingdom

Gastroenterology
W.B. Saunders | United States

Gut Microbes
Landes Bioscience | United States

JHEP Reports
Elsevier B.V. | Netherlands

Clinical Gastroenterology and Hepatology
W.B. Saunders | United States

Cellular and Molecular Gastroenterology and Hepatology
Elsevier Inc. | United States

Journal of Crohn's and Colitis
Oxford University Press | United Kingdom

Alimentary Pharmacology and Therapeutics
John Wiley and Sons Inc | United Kingdom

See All

Top Journals/Conferences in Immunology and Allergy

Nature Reviews Immunology
Nature Research | United Kingdom

Annual Review of Immunology
Annual Reviews Inc. | United States

Immunity
Cell Press | United States

Nature Immunology
Nature Research | United Kingdom

Science immunology
American Association for the Advancement of Science | United States

Cellular and Molecular Immunology
Springer Nature | United Kingdom

Journal of Experimental Medicine
Rockefeller University Press | United States

Annals of the Rheumatic Diseases
Elsevier B.V. | United Kingdom

Journal for ImmunoTherapy of Cancer
BMJ Publishing Group | United Kingdom

Journal of Allergy and Clinical Immunology
Elsevier Inc. | United States

See All

Top Journals/Conferences in Oncology

Ca-A Cancer Journal for Clinicians
John Wiley and Sons Inc | United States

Nature Reviews Clinical Oncology
Nature Publishing Group | United Kingdom

Nature Reviews Cancer
Nature Publishing Group | United Kingdom

Annals of Oncology
Elsevier Ltd | United Kingdom

Cancer Cell
Cell Press | United States

Nature Cancer
Nature Research | United States

Lancet Oncology, The
Elsevier Ltd | United Kingdom

Journal of Clinical Oncology
Lippincott Williams and Wilkins | United States

Journal of Hematology and Oncology
BioMed Central Ltd | United Kingdom

Molecular Cancer
BioMed Central Ltd | United Kingdom

See All

Top Journals/Conferences in Pharmacology (medical)

Drug Resistance Updates
Churchill Livingstone | United Kingdom

Pharmacology and Therapeutics
Elsevier Inc. | United States

Drugs
| Switzerland

Journal of Biomedical Science
BioMed Central Ltd | United Kingdom

npj Breast Cancer
Nature Publishing Group | United Kingdom

Alimentary Pharmacology and Therapeutics
John Wiley and Sons Inc | United Kingdom

American Journal of Transplantation
Elsevier B.V. | Netherlands

Acta Pharmacologica Sinica
Springer Nature | United Kingdom

BioDrugs
| Switzerland

npj Vaccines
Nature Publishing Group | United Kingdom

See All

Top Journals/Conferences in Rheumatology

Annals of the Rheumatic Diseases
Elsevier B.V. | United Kingdom

Nature reviews. Rheumatology
Nature Research | United Kingdom

Lancet Rheumatology, The
Elsevier Ltd | United Kingdom

Arthritis and Rheumatology
John Wiley and Sons Ltd | United Kingdom

Osteoarthritis and Cartilage
W.B. Saunders Ltd | United Kingdom

Seminars in Arthritis and Rheumatism
W.B. Saunders | United States

Current Rheumatology Reports
Springer | United States

Rheumatology
Oxford University Press | United Kingdom

Current Opinion in Rheumatology
Lippincott Williams and Wilkins | United States

RMD Open
BMJ Publishing Group | United Kingdom

See All